Tracked shipping to South Africa with premium packaging for just R199 

Ship to
South Africa
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada Do Pharmaceutical Mergers Harm Drug Innovation? De jan Schmidt(Grin Publishing)
Type
Physical Book
Publisher
Author
Language
English
Format
Paperback
ISBN13
9783656962175

Do Pharmaceutical Mergers Harm Drug Innovation? De jan Schmidt(Grin Publishing)

Schmidt Jan (Author) · Grin Publishing · Paperback

Do Pharmaceutical Mergers Harm Drug Innovation? De jan Schmidt(Grin Publishing) - Schmidt Jan

New Book Imported to South Africa
Delivery: 01 Oct - 09 Oct Shipping: 14 to 15 business days.
R 579
R 579

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "Do Pharmaceutical Mergers Harm Drug Innovation? De jan Schmidt(Grin Publishing)"

Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies' mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation. Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews